Dr. Berna Sozen's Vilcek Prize win signals a major shift in biomedical science funding and the hidden battle for top immigrant talent.
Forget incremental advances. The 2026 life science predictions hide a brutal consolidation plan. Discover the hidden winners in the coming biotech restructuring.
Is the fusion of AI and translational science in ALS care a miracle, or a calculated move for data dominance? We dissect the hidden costs.
The Digital Health Rewired 2026 program is out, but we dissect the hidden power plays driving future healthcare tech adoption.
Anthropic is pushing Claude into life sciences, but the real story isn't better diagnoses—it's who controls the new medical intelligence bottleneck.
Anthropic is pushing Claude into healthcare, but the real battle isn't clinical success; it’s controlling the future of proprietary medical data.
OpenAI's entry into healthcare isn't about better diagnoses; it's a calculated move to shift medical accountability. We analyze the real winners and losers in this AI power grab.
The FDA's new oversight rules for AI and wearables aren't about safety—they're about control. Unpacking who truly benefits from this regulatory shift.
Forget the hype around personalized medicine. The real story behind 2025's health innovations is the quiet consolidation of your most intimate data.
AI is boosting neuroprotective drug trials for stroke, but who truly profits from this precision medicine revolution? The real battle is over data ownership.
The persistent error rate in medical AI isn't a bug; it's a feature of the system. Discover who profits from this calculated risk in healthcare.